Literature DB >> 14982791

In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus.

Eric Dannaoui1, Olivier Lortholary, Françoise Dromer.   

Abstract

Microdilution broth checkerboard techniques based on the National Committee for Clinical Laboratory Standards methodology were used to study double and triple antifungal combinations against clinical isolates of Aspergillus fumigatus and A. terreus. The influences of the end-point definition (partial or complete inhibition) and the mode of reading (visually or spectrophotometrically) were determined. Interactions between antifungal drugs were also evaluated by agar diffusion tests. Combinations of caspofungin with either amphotericin B or voriconazole were additive for all the isolates, and antagonism was not observed. The interaction between caspofungin and flucytosine was synergistic for 62% of the isolates. In contrast, the interaction between voriconazole and flucytosine was never synergistic and antagonism was noted for 93% of the isolates. The triple combination of caspofungin with flucytosine and amphotericin B was synergistic for all the isolates tested. The triple combination of caspofungin with flucytosine and voriconazole was also mostly synergistic; but complex interactions were obtained for some isolates, with synergy or antagonism depending on the concentrations of caspofungin and voriconazole. Analysis of the influence of the reading technique on the results showed that spectrophotometric reading was a good alternative to the recommended visual reading. The results of these in vitro tests suggest that the activity of flucytosine as part of a double combination with caspofungin and as part of a triple combination with caspofungin and amphotericin B against Aspergillus spp. warrants further investigations. Animal studies are needed to evaluate the in vivo efficacies of these combinations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982791      PMCID: PMC353155          DOI: 10.1128/AAC.48.3.970-978.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 2.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

3.  In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.

Authors:  J Mosquera; A Sharp; C B Moore; P A Warn; D W Denning
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

4.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

5.  In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

Authors:  Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

7.  Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.

Authors:  Timothy B Aliff; Peter G Maslak; Joseph G Jurcic; Mark L Heaney; Kathleen N Cathcart; Kent A Sepkowitz; Mark A Weiss
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

8.  In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Authors:  Sofia Perea; Gloria Gonzalez; Annette W Fothergill; William R Kirkpatrick; Michael G Rinaldi; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

9.  In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points.

Authors:  Itamar Shalit; Yona Shadkchan; Zmira Samra; Nir Osherov
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

10.  Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter.

Authors:  Thierry Noël; Fabienne François; Patrick Paumard; Christiane Chastin; Daniel Brèthes; Jean Villard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  33 in total

1.  Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Authors:  Donna M MacCallum; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.

Authors:  Virginie Planche; Sebastien Ducroz; Alexandre Alanio; Marie-Elisabeth Bougnoux; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

3.  In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Deanna Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

4.  Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation.

Authors:  Stéphanie Ruiz; Emmanuelle Papy; Daniel Da Silva; Patrick Nataf; Laurent Massias; Michel Wolff; Lila Bouadma
Journal:  Intensive Care Med       Date:  2008-09-16       Impact factor: 17.440

5.  Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for Mucorales Species.

Authors:  Pauline Vidal; Patrick Schwarz; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Species Identification and In Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Clinical Isolates from a French Multicenter Study.

Authors:  E Dannaoui; F Botterel; S Imbert; A C Normand; S Ranque; J M Costa; J Guitard; I Accoceberry; C Bonnal; A Fekkar; N Bourgeois; S Houzé; C Hennequin; R Piarroux
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

9.  Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

Authors:  Joanne P Demchok; Joseph Meletiadis; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-03-07       Impact factor: 4.377

10.  Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.

Authors:  V Nagappan; D Boikov; J A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.